IQVIA Holdings (IQV) has raised its full-year 2026 revenue outlook to a range of US$17.35b to US$17.5b after reporting third quarter and year-to-date earnings per share figures.
At a share price of US$264.88, IQVIA Holdings has delivered a 17.53% year to date share price return and a 25.62% total shareholder return over the past 12 months, with the 10.97% 90 day share price gain suggesting momentum has been building into the latest guidance and earnings update.
Scan how IQVIA Holdings fits alongside other hand picked healthcare AI plays by reviewing the 34 healthcare AI stocks that could also be seeing sentiment build around guidance and earnings updates.
IQVIA Holdings now trades about 15% below the average analyst target and sits at a deeper discount to estimated intrinsic value. After the recent run, is that caution sensible or overly harsh on the story here?
Most Popular Narrative: 12% Undervalued
IQVIA Holdings is described as undervalued in the most widely followed narrative, with a fair value of $302.67 compared with the last close at $264.88. That gap is being linked directly to how effectively the business can translate its AI and contract research pipelines into future earnings.
The main factor highlighted is that IQVIA Holdings continues to convert strong R&DS bookings, a large backlog and growing Commercial Solutions activity, including with emerging biopharma customers, into sustained revenue and earnings growth despite margin and debt headwinds.
See why 19 investors see IQVIA Holdings as 12% undervalued.
Result: Fair Value of $302.67 (UNDERVALUED)
Still, the IQVIA Holdings story can be knocked off course if CRO pricing pressure squeezes margins or if pharma clients build more AI and data tools in-house, reducing demand for its platforms.
Find out about the key risks to this IQVIA Holdings narrative.
Another View On IQVIA Holdings Valuation
The story changes once the focus moves from future cash flows to the current P/E ratio. IQVIA Holdings trades on 31.3x earnings, which screens as good value against both peers at 37.2x and the global life sciences group at 36.3x. However, it sits slightly above its own fair ratio of 30.4x, which hints at some valuation risk if sentiment cools.
This split picture, with cash flow work pointing to upside and the earnings multiple already leaning toward full, raises a simple question for investors: Which signal should carry more weight in your process when you think about IQVIA.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages on IQVIA Holdings valuation and sentiment can be useful if you act fast and test the claims against your own process using the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond IQVIA Holdings?
If IQVIA Holdings has sharpened your focus, now is the moment to widen your net and pressure test your thesis against other compelling opportunities.
- Target resilient balance sheets and steadier risk profiles by scanning a list of solid balance sheet and fundamentals (24 results) that can help you stress test your defensive picks.
- Hunt for quality at a price that may still leave room for upside by reviewing a curated 42 high quality undervalued stocks tailored to fundamental strength.
- Spot less widely followed opportunities with strong underlying metrics by running through a focused 21 high quality undiscovered gems before attention and liquidity move elsewhere.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com